Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Documenti analoghi

• Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
  di: Wang, Wei, et al.
  Pubblicazione: (2016)
• Outcome of Treatment of CML with 2(nd) Generation Tyrosine Kinase Inhibitors After Imatinib Failure
  di: Cornelison, A. Megan, et al.
  Pubblicazione: (2011)
• Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
  di: Gong, Zimu, et al.
  Pubblicazione: (2017)
• How I treat newly diagnosed chronic phase CML
  di: Cortes, Jorge, et al.
  Pubblicazione: (2012)
• Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
  di: Höglund, Martin, et al.
  Pubblicazione: (2013)